SCHEDULE: Sabby Entities Disclose 4.9% Passive Stake in Universe Pharmaceuticals

Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly disclosed a passive 4.9% beneficial ownership in Universe Pharmaceuticals INC's Ordinary Shares as of December 31, 2025.

Summary

• Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz collectively reported beneficial ownership of 28,111 Ordinary Shares of Universe Pharmaceuticals INC.
• This ownership represents 4.9% of the company's outstanding Ordinary Shares.
• All reporting persons have shared voting power and shared dispositive power over the 28,111 shares, with no sole voting or dispositive power.
• The filing is an Amendment No. 1 to a previous Schedule 13G, indicating an update to a prior ownership disclosure.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing the control of Universe Pharmaceuticals INC.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive beneficial ownership, indicating a neutral sentiment. It neither provides positive nor negative operational news about the company.

Positives

• A notable investment firm, Sabby Management, and its affiliates hold a significant, albeit passive, stake in Universe Pharmaceuticals INC, which could be interpreted as a vote of confidence in the company's long-term prospects.
• The passive nature of the stake, as certified by the filers, suggests no immediate intent to influence company control, which can provide stability for current management and strategic direction.

Negatives

• The reported stake of 4.9% is below the 5% threshold that would typically trigger more detailed disclosure requirements (Schedule 13D) if the intent were active, indicating a purely passive investment with no stated intention to engage in corporate governance or strategic changes.
• The filing does not provide any specific positive or negative commentary on Universe Pharmaceuticals INC's operational performance, financial health, or future outlook.

Risks

• The filing itself does not detail risks related to Universe Pharmaceuticals INC's business operations or financial performance.
• For the reporting persons, the investment carries the inherent market risk associated with the performance of Universe Pharmaceuticals INC's Ordinary Shares.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by institutional investors might be viewed as a minor positive signal, but the overall impact is generally limited given the passive nature and the stake being below the 5% threshold.
• Management: Awareness of a significant passive shareholder group, but no direct impact on operations or strategy is implied by this filing.

Key Dates

Recommendation

This Schedule 13G filing merely discloses a passive beneficial ownership stake of 4.9% by Sabby Management and its affiliates. It does not provide any new financial or operational information about Universe Pharmaceuticals INC that would warrant a change in investment recommendation. The certification of passive intent suggests no immediate catalyst for significant corporate action. Investors should 'hold' and await further operational or financial disclosures from the company to make informed decisions.

Keywords

Universe Pharmaceuticals INC, Ordinary Shares, Sabby Management, Sabby Volatility Warrant Master Fund, Hal Mintz, Beneficial Ownership, Schedule 13G, Passive Investment, Equity Stake, SEC Filing